# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN-TD
- Date: 1955-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to stop needing pills to sleep and to work, without being made to feel she is to blame for them **S**
- She is afraid of being unable to sleep or perform during the change **S**
- She worries about her weight if she stops the stimulant **S**

## Your goals

- Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium. Target: 1955-07-20. Recorded outcome: Four-day supervised admission; no seizure, delirium or severe withdrawal. **S**
- Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping. Target: 1955-10-26. Recorded outcome: 97.2 mg a day at discharge to 32.4 mg a day at four months; two pauses when needed; taper continuing. **S**
- Stop dextroamphetamine with a short taper and no return to it. Target: 1955-08-31. Recorded outcome: Stopped after a two-week taper; tiredness for about two weeks, then better. **S**
- Sleep six hours or more on most nights using CBT for insomnia. Target: 1955-10-26. Recorded outcome: About six hours on most nights; rebound wakefulness after each dose step settles within a week. **S**
- PHQ-9 below 5 by six months. Target: 1955-10-26. Recorded outcome: PHQ-9 14 to 5 at four months; response. **S**
- Regular meals and weight she is comfortable with, without dieting drugs. Target: 1955-10-26. Recorded outcome: Three meals on most days; weight up 3.5 kg to a BMI of 21.9; she says she feels stronger. **S**

## What we agreed to do

- Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsules. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to confirm the diagnoses, plan a safe barbiturate withdrawal and taper, and advise on stopping the stimulant. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Supervised barbiturate withdrawal: a short hospital admission to change secobarbital to phenobarbital with withdrawal scoring and seizure precautions, then a slow outpatient phenobarbital taper of no more than about 20% every two weeks, slower toward the end, paused for withdrawal symptoms, illness or a major performance, never stopped abruptly; no benzodiazepine or Z-drug in its place; no alcohol. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020) **S**
- Stimulant: dextroamphetamine held at one fixed morning dose until phenobarbital is stable, then 5 mg for two weeks and stopped, with mood, sleep and appetite checks; no other stimulant. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnotic. Guideline: Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016) **S**
- Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eating. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternative. Guideline: U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**
- Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacy. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controls. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**

## Follow-up

- 1955-06-22: Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth **S**
- 1955-06-29: One-week review with the addiction medicine consultation: planning a supervised barbiturate withdrawal **S**
- 1955-07-20: Four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taper **S**
- 1955-08-31: Ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and work **S**
- 1955-09-28: Periodic adult preventive visit **S**
- 1955-10-26: Four-month review: phenobarbital taper, sleep, mood, laboratory checks and the plan to finish **S**

This teaching document does not replace care from a qualified clinician.
